Best Practices For Conducting Multinational Clinical Trials | Page 2

Demystifying Asia: Best Practices For Conducting Multinational Clinical Trials
Introduction »

Figure 1.

Why Go To Asia With Your Clinical Trial?

speed enrollment. This paper reviews issues around conducting clinical

N
O
TI
LA
PU
PO

growing interest in accessing multinational patient populations to

T
EN
TI
PA

companies to bring more products to market faster, there has been

DA S
TA IMI
Q LA
UA R
LI
TY

With increasing need for pharmaceutical and biotechnology

trials in select Asian countries, starting with general benefits, followed by
discussion of country-specific considerations for protocol development,
regulatory requirements, and recruitment and concluding with the
advantages of partnering with an experienced global contract

N
O
TI
EC
OT
PR

Population and Age of Select Countries in Asia

IP

Table 1.

H
ST ARM
AN O
DA NI
RD ZAT
O ION
FC
AR OF
E

research organization (CRO).

Why go to Asia with your clinical trial? »
When sponsors or CROs consider conducting clinical trials in Asia,
the biggest perceived advantage is the availability of patients. Asia,
as a whole, represents 60% of the world’s population, while select
Asian countries (Table 1) have a combined total of 1.7 billion people,
representing 25% of the world’s population.
There is also a growing Asian pharmaceutical and clinical trials market,
with growth in Asia continuing at double-digit rates.1 Furthermore, R&D
investment increased more than 20-fold between 2000 and 2010.2 This
may reflect the interest in expanding the pharmaceutical market, but
Based on 2014 estimates by the CIA (CIA factbook)
* Countries in which Clinipace Worldwide maintains Asian offices.

also an increased awareness of health issues within these countries.

clinipace.com

1